Semmelweis Egyetem, I. Sz. Patológiai és Kísérleti Rákkutató Intézet, Budapest
Genetic fusions are the cosequence of genomic rearrangement including chromosomal inversion, interstitial deletion, duplication, ampliﬁ cation, translocation. Fusions can inﬂ uence tumor development and progression. Fusions ﬁ rst discovered in hematological malignances (e.g. BCR-ABL), butlater more and more were identiﬁ ed dueto the higly sensitive NGS. It has been found that the oncogenic fusions are in minority in a given tumor. Today, some fusions were apprevedas targets (ALK, ROS1, PDGFB) by FDA. Asino ther targeted therapy resistance is in evitable, which is a very important challenge for newly designed drugs.